ABSTRACT
BACKGROUND: Aging is a complex irreversible process that is not only related to an individual's genetic make-up but also to lifestyle choices and environmental exposures. Like every other structure in human body, the Neuromuscular Junction (NMJ) is not averse to aging. OBJECTIVES: The prime objective is to analyse the microscopic and macroscopic changes at the NMJs with aging. METHODS: For the purpose of review we evaluated data from resources like Pubmed, Ovid, UCLA libraries and USC libraries. RESULTS: We review various morphological, physiological, immunological, and biochemical changes in NMJs with aging and their management. CONCLUSION: The alterations in NMJs secondary to aging are inevitable. It is vital that neurologists clearly understand the pathophysiology of NMJ aging and differentiate between physiological and pathological effects of aging. With the current knowledge of science, the changes in NMJ aging can be better prevented rather than cured.
Subject(s)
Aging/physiology , Geriatric Assessment/methods , Neuromuscular Junction/physiopathology , Primary Prevention , Synapses/metabolism , Age Factors , Aged , Aged, 80 and over , Animals , Databases, Factual , Female , Follow-Up Studies , Humans , Male , Mice , Molecular Biology , Risk AssessmentABSTRACT
Sjögren's syndrome (SS) is a chronic autoimmune disorder, characterized by lymphocytic infiltration of exocrine glands and causing the decreased function of lacrimal and salivary glands. We describe a case of a 34-year-old male who presented with Sjögren's syndrome presenting as myopathy and sensorimotor neuropathy. His creatinine kinase levels were elevated with positive anti-Sjögren's syndrome-related antigen A autoantibodies and anti-Sjögren's syndrome Type B autoantibodies. Electromyography showed evidence of irritable myopathy. Parotid gland biopsy demonstrated focal lymphocytic sialadenitis. The patient favorably responded to high-dose steroids. Thus, although rare, inflammatory myopathy must be considered part of the initial presentation of Sjögren's syndrome.
ABSTRACT
Hydroxychloroquine (HCQ) and chloroquine are used worldwide for malaria as well as connective and rheumatological disorders. They have been reported to be linked to myopathy in patients. We report four patients who were receiving HCQ as part of treatment for connective tissue disorder and who presented with myopathy. The muscle biopsy in these patients was consistent with findings of HCQ toxicity. HCQ muscle toxicity is usually self-limiting after discontinuation of the drug. It also usually tends to be under-reported due to presence of various confounding factors. This warrants close monitoring and consideration of muscle biopsy as part of initial work up of patients who present with myopathy while receiving HCQ.
